These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

456 related items for PubMed ID: 9753311

  • 1. Effects on hemostatic variables of desogestrel- and gestodene-containing oral contraceptives in comparison with levonorgestrel-containing oral contraceptives: a review.
    Winkler UH.
    Am J Obstet Gynecol; 1998 Sep; 179(3 Pt 2):S51-61. PubMed ID: 9753311
    [Abstract] [Full Text] [Related]

  • 2. Population-based study of risk of venous thromboembolism associated with various oral contraceptives.
    Farmer RD, Lawrenson RA, Thompson CR, Kennedy JG, Hambleton IR.
    Lancet; 1997 Jan 11; 349(9045):83-8. PubMed ID: 8996419
    [Abstract] [Full Text] [Related]

  • 3. Oral contraceptives and venous thromboembolic disease: the findings from database studies in the United Kingdom and Germany.
    Farmer RD, Lawrenson RA.
    Am J Obstet Gynecol; 1998 Sep 11; 179(3 Pt 2):S78-86. PubMed ID: 9753314
    [Abstract] [Full Text] [Related]

  • 4. Modern oral contraceptives and cardiovascular disease.
    Rosenberg L, Palmer JR, Sands MI, Grimes D, Bergman U, Daling J, Mills A.
    Am J Obstet Gynecol; 1997 Sep 11; 177(3):707-15. PubMed ID: 9322646
    [Abstract] [Full Text] [Related]

  • 5. The effect of oestrogen dose and progestogen type on haemostatic changes in women taking low dose oral contraceptives.
    Norris LA, Bonnar J.
    Br J Obstet Gynaecol; 1996 Mar 11; 103(3):261-7. PubMed ID: 8630312
    [Abstract] [Full Text] [Related]

  • 6. Bias versus causality: interpreting recent evidence of oral contraceptive studies.
    Spitzer WO.
    Am J Obstet Gynecol; 1998 Sep 11; 179(3 Pt 2):S43-50. PubMed ID: 9753310
    [Abstract] [Full Text] [Related]

  • 7. Risk of idiopathic cardiovascular death and nonfatal venous thromboembolism in women using oral contraceptives with differing progestagen components.
    Jick H, Jick SS, Gurewich V, Myers MW, Vasilakis C.
    Lancet; 1995 Dec 16; 346(8990):1589-93. PubMed ID: 7500750
    [Abstract] [Full Text] [Related]

  • 8. Low-dose oral contraceptives and acquired resistance to activated protein C: a randomised cross-over study.
    Rosing J, Middeldorp S, Curvers J, Christella M, Thomassen LG, Nicolaes GA, Meijers JC, Bouma BN, Büller HR, Prins MH, Tans G.
    Lancet; 1999 Dec 11; 354(9195):2036-40. PubMed ID: 10636369
    [Abstract] [Full Text] [Related]

  • 9. Newer oral contraceptives and the risk of venous thromboembolism.
    Walker AM.
    Contraception; 1998 Mar 11; 57(3):169-81. PubMed ID: 9617533
    [Abstract] [Full Text] [Related]

  • 10. Effect of oral contraceptive progestins on serum copper concentration.
    Berg G, Kohlmeier L, Brenner H.
    Eur J Clin Nutr; 1998 Oct 11; 52(10):711-5. PubMed ID: 9805216
    [Abstract] [Full Text] [Related]

  • 11. Effects of oral contraceptives on hemostasis and thrombosis.
    Rosing J, Tans G.
    Am J Obstet Gynecol; 1999 Jun 11; 180(6 Pt 2):S375-82. PubMed ID: 10368524
    [Abstract] [Full Text] [Related]

  • 12. Estrogen and progestin components of oral contraceptives: relationship to vascular disease.
    Carr BR, Ory H.
    Contraception; 1997 May 11; 55(5):267-72. PubMed ID: 9220222
    [Abstract] [Full Text] [Related]

  • 13. Haemostatic changes and the oral contraceptive pill.
    Norris LA, Bonnar J.
    Baillieres Clin Obstet Gynaecol; 1997 Sep 11; 11(3):545-64. PubMed ID: 9488791
    [Abstract] [Full Text] [Related]

  • 14. What is the risk of venous thromboembolism (VTE) among women taking third-generation oral contraceptives (OCs) in comparison with those taking contraceptives containing levonorgestrel?
    Meurer LN, Slawson JG.
    J Fam Pract; 2001 Feb 11; 50(2):108. PubMed ID: 11219554
    [No Abstract] [Full Text] [Related]

  • 15. The use of oral contraceptives and the occurrence of acute myocardial infarction in young women. Results from the Transnational Study on Oral Contraceptives and the Health of Young Women.
    Lewis MA, Heinemann LA, Spitzer WO, MacRae KD, Bruppacher R.
    Contraception; 1997 Sep 11; 56(3):129-40. PubMed ID: 9347202
    [Abstract] [Full Text] [Related]

  • 16. Thrombotic diseases in young women and the influence of oral contraceptives.
    Lidegaard O.
    Am J Obstet Gynecol; 1998 Sep 11; 179(3 Pt 2):S62-7. PubMed ID: 9753312
    [Abstract] [Full Text] [Related]

  • 17. Coagulation and anticoagulation effects of contraceptive steroids.
    Samsioe G.
    Am J Obstet Gynecol; 1994 May 11; 170(5 Pt 2):1523-7. PubMed ID: 8178901
    [Abstract] [Full Text] [Related]

  • 18. Enhancement by factor V Leiden mutation of risk of deep-vein thrombosis associated with oral contraceptives containing a third-generation progestagen.
    Bloemenkamp KW, Rosendaal FR, Helmerhorst FM, Büller HR, Vandenbroucke JP.
    Lancet; 1995 Dec 16; 346(8990):1593-6. PubMed ID: 7500751
    [Abstract] [Full Text] [Related]

  • 19. Effects on hemostasis after two-year use of low dose combined oral contraceptives with gestodene or levonorgestrel.
    Prasad RN, Koh SC, Viegas OA, Ratnam SS.
    Clin Appl Thromb Hemost; 1999 Jan 16; 5(1):60-70. PubMed ID: 10725985
    [Abstract] [Full Text] [Related]

  • 20. The effects on hemostasis of oral contraceptives containing desogestrel.
    Stubblefield PG.
    Am J Obstet Gynecol; 1993 Mar 16; 168(3 Pt 2):1047-52. PubMed ID: 8447359
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 23.